Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Short term Debt (2016 - 2023)

Cartesian Therapeutics (RNAC) has disclosed Short term Debt for 8 consecutive years, with $28.3 million as the latest value for Q4 2023.

  • On a quarterly basis, Short term Debt rose 233.97% to $28.3 million in Q4 2023 year-over-year; TTM through Dec 2023 was $28.3 million, a 233.97% increase, with the full-year FY2023 number at $28.3 million, up 233.97% from a year prior.
  • Short term Debt was $28.3 million for Q4 2023 at Cartesian Therapeutics, up from $10.2 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $28.3 million in Q4 2023 to a low of $460000.0 in Q1 2021.
  • A 5-year average of $11.1 million and a median of $8.5 million in 2022 define the central range for Short term Debt.
  • Peak YoY movement for Short term Debt: plummeted 97.27% in 2021, then soared 1368.1% in 2023.
  • Cartesian Therapeutics' Short term Debt stood at $18.9 million in 2019, then crashed by 55.65% to $8.4 million in 2020, then decreased by 28.9% to $6.0 million in 2021, then skyrocketed by 42.19% to $8.5 million in 2022, then soared by 233.97% to $28.3 million in 2023.
  • Per Business Quant, the three most recent readings for RNAC's Short term Debt are $28.3 million (Q4 2023), $10.2 million (Q2 2023), and $10.2 million (Q1 2023).